SinoPharm: COVID-19 vaccine could be ready by end of 2020 – Global Times

Dhwani Mehta FXStreet

In an interview with China’s highly influential media outlet, Global Times, Liu Jingzhen, Chairman of China National Pharmaceutical Group (SinoPharm), said the results of phase I and II clinical trials of the coronavirus vaccine were very positive and without serious side effects.

Key quotes

"SinoPharm was approved at the end of June to begin international phase III clinical trials and [the vaccine] could be on the market by the end of the year."

“Phase III trials should be completed in about three months and are in the final stages of approval.”

"So far, it's going well. It is leading the world in research and development, clinical trials, manufacturing facilities, and vaccine efficacy, safety, and accessibility."

In the US, three vaccines were under research and development in the first half, including those from Moderna and Pfizer.

Other COVID-19 vaccines are also in development - including one at the University of Oxford in the UK - and have also entered clinical trials.

Market reaction

The risk sentiment remains tepid amid intensifying US-China tensions over the Houston consulate episode. This negates any optimism over the vaccine hopes and economic recovery so far this Thursday.

AUD/USD trades listless around 0.7135 while S&P 500 futures also lack a clear direction to trade above 3,250. Meanwhile, the Asian equities trade mostly lower, with Japanese markets closed on a long break.

Author

Dhwani Mehta

FXStreet

Residing in Mumbai (India), Dhwani is a Senior Analyst and Manager of the Asian session at FXStreet. She has over 10 years of experience in analyzing and covering the global financial markets, with specialization in Forex and commodities markets.

GBP/USD clings to multi-day peaks below 1.3500

GBP/USD trades with marked gains on Friday, now giving away some gains following an earlier surpass of the key 1.3500 yardstick. Indeed, Cable gathers fresh steam amid the strong offered stance in the Greenback, all after US NFP badly missed expectations in July.

EUR/USD: Post-NFP bounce falters around 1.1580

EUR/USD reverses Thursday’s decline and trades with solid gains in the 1.1560 region, or two-month peaks, on Friday. The pair’s firm performance comes in a context of a sharp correction in the US Dollar as investors continue to assess disheartening US NFP readings.

How Wall Street rigs the game [Video]

In this week’s Live from the Vault, Andrew Maguire is joined by Peter Antico and Sean Stone to discuss the Paradigm of Money - an in-depth expose of financial market corruption, from naked shorting to the two-tier system that protects Wall Street.

XRP Price Forecast: XRP nears critical $1.00 support

Ripple (XRP) remains pressured on Friday, trading around $1.03 at the time of writing. The token appears to hold this current level as support but lacks a catalyst to sustain a knee-jerk rebound toward the next key resistance at $1.10.

Is Gold about to enter its biggest bull run since 2020?

Gold has stormed back into the spotlight and its next move could leave late buyers chasing. On August 5, the yellow metal surged almost 7% – roughly $174 – to close near $4,308 an ounce, posting one of its biggest daily advances in recent history. A weaker U.S dollar, falling Treasury yields, changing Federal Reserve expectations and renewed safe-haven demand all struck at once.

9-3: Is the Federal Reserve’s vote tally Warsh's new forward guidance?

The rate did not move. Neither did the statement, and that’s the more interesting fact. Set the July 29 Federal Open Market Committee (FOMC) statement beside the one issued on June 17, and the two documents are identical apart from a single verb and a paragraph at the bottom naming three dissenters.